Covishield Production to Resume: SII Announces Amid Surge in COVID-19 Cases
The Serum Institute of India (SII), the
world's largest vaccine manufacturer, recently announced that it would resume
production of the Covishield vaccine after a brief pause. The announcement
comes amid a surge in COVID-19 cases in India, where the virus is spreading at
an alarming rate.
Covishield, developed by AstraZeneca and
the University of Oxford, is one of two vaccines currently being administered
in India's nationwide vaccination drive. The other vaccine, Covaxin, was
developed by the Indian pharmaceutical company Bharat Biotech. Both vaccines
require two doses to provide full immunity against COVID-19.
The SII had put its production on hold
earlier this month after the Indian government placed a temporary ban on the
export of the vaccine to meet domestic demand. The ban was imposed after a
sudden surge in COVID-19 cases across the country, which has led to a shortage
of vaccines in some states.
The resumption of Covishield production
by the SII is good news for India, as it will help to ensure a steady supply of
vaccines in the coming weeks and months. The SII has played a crucial role in
India's vaccination drive, producing more than 100 million doses of the vaccine
so far.
However, the SII's decision to resume
production is also likely to face challenges, as the company is facing a
shortage of raw materials needed to produce the vaccine. The company has
reportedly asked the Indian government to waive the ban on exporting raw
materials needed for vaccine production so that it can meet its production
targets.
The situation in India remains grim,
with daily COVID-19 cases continuing to rise. The country has reported more
than 200,000 new cases each day for the past week, and the death toll has
surpassed 180,000. Hospitals in many states are overwhelmed, and there is a
shortage of oxygen and other medical supplies needed to treat COVID-19
patients.
The Indian government has been taking
steps to address the situation, including ramping up vaccine production and
increasing the supply of medical oxygen. The government has also imposed restrictions
on public gatherings and travel in some states to help slow the spread of the
virus.
In conclusion, the resumption of
Covishield production by the SII is a positive development in India's fight
against COVID-19. However, the situation remains challenging, and the country
needs all the help it can get to overcome the current crisis. The global
community must come together to support India in its efforts to tackle the
pandemic, as it is in everyone's best interest to ensure that the virus is brought
under control as soon as possible.
Comments
Post a Comment